 Despite recent advances in malaria vaccines, the PFSPZ Sanaria registered trademark symbol vaccine remains the only whole sporozoic vaccine with nearly 100% efficacy undergoing extensive clinical testing. Alternative approaches include immunization with fully infectious sporozoids under chloroquine prophylaxis or as genetically attenuated parasites, and combining these with controlled doses of sporozoids for challenge studies. This article was authored by Michaela Hollingdell and Martha Sediga.